Derma Sciences (DSCI -1.6%) says it's initiated patient enrollment in the first of two Phase 3...

|About: Derma Sciences Inc. (DSCI)|By:, SA News Editor

Derma Sciences (DSCI -1.6%) says it's initiated patient enrollment in the first of two Phase 3 clinical trials for its investigational topical drug candidate DSC127. The two trials are designed to assess the safety and efficacy of DSC127 in chronic, non-healing diabetic foot ulcers and to support the filing of a New Drug Application with the FDA.